{"name":"Biotheryx, Inc.","slug":"biotheryx-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxObS14RFJfMEZOSl94UDktWFc0cUpPWXZMdlFkanlRek14WXBnbUNVdG9wT0dLN1BMYmhXQ2FKc1dGRDNFV281WFhXU0NRZDNTM2laVVVPdFpjOGFsSU5OVDBQWmNkNG55cmFpeFdMcGFvM1BZb3ZCalA3d2NzaTYyTjNuUzVRS3RYeDZXaW1TVjBLY0xickdCX0dLZEJoWHFVQko4TUJmYndhSERKT1cySm9CS2k1ZXRYeUl3cGNyOXZCSU9PbU9sUFU3S3I1VUZzRHJSUVNJSVFjMDhodkhja28yYUZGdk1jcDhYd2loQVlkMy1fbUtUYjJVcUxacWowdlo1VzJFY2pVNFk?oc=5","date":"2025-11-17","type":"trial","source":"PR Newswire","summary":"Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast Cancer - PR Newswire","headline":"Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"PR Newswire","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQcVRKMlB2eE1ia3U5Tllxc3k1c2lGZGVCaDR6UUg2ZUtpbV9YNzViMTJwM2ZVZXcxMVNBS1d2VC1YZ0JlWGhsSE1xN2N1R1YxRHhWczlrUnRrd1FJT0NnWFZtUnhZRGZxcGZ1bXBvam0zVnFBNVcwWC1fUFVNcE1DeWZPeG1WcmI4NWdUQ1RoSjA2LVZ5MUNSTllvT2JMTjJKdFd6TkpwWmdhaDJpeXFwMWlhOThhY0RSWk5IU29tdU9oS19j?oc=5","date":"2023-04-07","type":"pipeline","source":"drugdiscoverytrends.com","summary":"BioTheryX and Incyte collaborate on molecular glue degraders - drugdiscoverytrends.com","headline":"BioTheryX and Incyte collaborate on molecular glue degraders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxPQnFOSXpvY1JRLTZNMkZycGhVWFNvWkJFenF0OEFMa0VGV0FKWFJPVFBOMFN4ZWtuNm9DcUJPbEN6TUYxb2dQc3dpQVo3dm95cThMZ2tmRi1RVXJ5cDdkdTRZWTd2UG11NTZRS3ItVlA2NXZKNVZDWk5WVThYVGtOOWRjRzZDSDF6QVR2LTdaM2lZa2VOY2N4Y3ZsalpOUEhJZTV3TmpaemxHMlVJU01XZWh4dnVibE1XbFl2VHlBWW4wMUc3a1JzMjNFdHp5cm91NEF6UmcyZlJIVFl3dF9GRk5nWVZKUjgycTU1bUduTTAwRERyd1VNU0ZNa1VNRjItVUhKV2tWSXFMN0hpdnZhWnJaVGk2dDYyM0ItUFp2NlhGNlowb3owZzd0NA?oc=5","date":"2023-04-05","type":"deal","source":"PR Newswire","summary":"Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets - PR Newswire","headline":"Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPS2VHeXpxRU9EblVuNHBFdzZyZHZkY1Q4TkRyUndidDNhV24zQVdqbVd0SVRzT0FNdFc5cHF5RUY1TC1tVmJlZ1lBb2N1TDVKNnZVNWd0dGN5bmdoajdHRVdmYkFmMWhjV0hVeDd0MGZ5OTJ0RHhaTjRTV1ZxaEluSkgtRHJhVlFVMGpFbnpOM0F5VG9tazV4Y2h3NEZ4RmNiTkR2cGcxNndPN0NUN0tOLWk5dUdtNk9qeUtiWWdmbDF2WW8zS3NYZ3hzOWVlZ3o1X3JGRjNPbW5aMHh4bDlSNWNoR2U0Q3FaTFlyN052RWFQaGw4ZU5KTGZQVUEzNkhjWEVsQ2l0TQ?oc=5","date":"2022-10-24","type":"pipeline","source":"Business Wire","summary":"Triumvira Immunologics Appoints Life Sciences Industry Leader Robert Williamson as President and Chief Business Officer - Business Wire","headline":"Triumvira Immunologics Appoints Life Sciences Industry Leader Robert Williamson as President and Chief Business Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZU42X0hadXJfcjI2bEcwaG5RaVJCZUw4cmg0dXVBYmkyV2lWWWwwZ2tkVmZmaVhxSEFZa3BteC1BeDNUUFJmVF9XTEtVVFJfRENfYWZremZ5MTd2bW03QVY0eEFJaG5fN3daS2lldXJndkNLYll0MVBSd0JGN1UzY0daVWVuQWlnMXlCdFhRNm1wTV84MXpJSTBpblpHSzJtZnlER1p6VDNqWDF6ODQ1aWhpNWlOVXlMUDl4UmwyRTI?oc=5","date":"2021-05-21","type":"pipeline","source":"Fierce Biotech","summary":"Left out of SPAC pack, BioTheryX raises $92M in rare series E to hold over until potential end of year IPO - Fierce Biotech","headline":"Left out of SPAC pack, BioTheryX raises $92M in rare series E to hold over until potential end of year IPO","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}